DexCom/$DXCM
1D1W1MYTD1Y5YMAX
Capital at risk
About DexCom
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
- Ticker
- $DXCM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 11,050
- Headquarters
- San Diego, United States
- Website
- www.dexcom.com
DexCom Metrics
BasicAdvanced
$32B
33.39
$2.54
1.41
-
Price and volume
Market cap
$32B
Beta
1.41
52-week high
$92.59
52-week low
$54.11
Average daily volume
4.4M
Financial strength
Current ratio
1.733
Quick ratio
1.359
Long term debt to equity
0.526
Total debt to equity
0.514
Interest coverage (TTM)
46.68%
Profitability
EBITDA (TTM)
1,403.2
Gross margin (TTM)
62.47%
Net profit margin (TTM)
20.12%
Operating margin (TTM)
22.92%
Effective tax rate (TTM)
21.90%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
10.33%
Return on equity (TTM)
38.49%
Valuation
Price to earnings (TTM)
33.387
Price to revenue (TTM)
6.582
Price to book
12.19
Price to tangible book (TTM)
12.81
Price to free cash flow (TTM)
23.279
Free cash flow yield (TTM)
4.30%
Free cash flow per share (TTM)
3.638
Growth
Revenue change (TTM)
15.54%
Earnings per share change (TTM)
77.35%
3-year revenue growth (CAGR)
15.83%
10-year revenue growth (CAGR)
26.08%
3-year earnings per share growth (CAGR)
43.16%
10-year earnings per share growth (CAGR)
26.25%
What the Analysts think about DexCom
Analyst ratings (Buy, Hold, Sell) for DexCom stock.
Analyst projections of the future price of DexCom stock.
Bulls say / Bears say
Dexcom beat Q2 2026 revenue and EPS estimates with $1.31 billion in revenue (up 13% YoY) and adjusted profit of $0.70 per share versus $0.61 estimate, and raised full-year 2026 revenue guidance to $5.18–$5.25 billion, underscoring sustained demand for its CGM systems. (Reuters)
Results from the CONNECT randomized controlled trial presented at the ADA showed Dexcom G7 users achieved an average 1.6% A1C reduction over 26 weeks—0.9% greater than routine care—supporting expansion into Type 2 non-insulin markets. (Reuters)
The FDA cleared Dexcom’s Stelo Glucose Biosensor System as the first over-the-counter CGM for children aged two and older not using insulin, expanding its pediatric addressable market. (Reuters)
Shares fell 5.9% after Q1 2026 earnings despite a beat, as the retained full-year revenue guidance midpoint of $5.205 billion was slightly below the $5.226 billion consensus, highlighting investor sensitivity to modest outlook deviations. (Reuters)
A potential CMS decision on non-insulin Type 2 reimbursement is not expected until end-2026, with coverage only effective mid-2027, delaying access to millions of Medicare patients and extending revenue ramp uncertainty. (MarketBeat)
Q2 2026 organic revenue excluded $9.9 million of foreign exchange headwinds, indicating currency volatility could substantially pressure reported sales if adverse FX trends continue. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 27 Aug 2026.
DexCom Financial Performance
Revenues and expenses
DexCom Earnings Performance
Company profitability
Upcoming events
No upcoming events
DexCom News
AllArticlesVideos
Funds containing DexCom
AllUSDEURGBP
Fund name | Fund size | $DXCM weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.29% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.29% |
iShares Healthcare Innovation£DRDR | £1B | 1.29% |
iShares AI Adopters and Applications€AIAA | €169M | 0.59% |
iShares AI Adopters and Applications£AIAA | £145M | 0.59% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.